Imatinib is approved for the treatment of chronic myelog-enous leukaemia (CIVIL) as well as gastrointestinal stromal tumour (GIST), both of which show dysregulated imatinib-sensitive tyrosine kinase activity. Imatinib is rapidly absorbed after oral administration (bioavailability 86%) and is mainly metabolized by the CYP3A4 and CYP3A5 isoenzymes of the liver [1]. Although the drug is usually well-tolerated, grade 1-2 adverse effects, such as muscu-loskeletal events, are frequently observed [2-4]. In a phase I clinical trial in patients with CIVIL, the minimum therapeutic dose of imatinib required to obtain an optimal therapeutic response was determined to be 300 mg day~(-1). However, the maximum tolerated dose has not yet been defined. In addition, there have been few case reports of imatinib overdose [5]. We herein report the results of a vpharmacokinetic analysis in a patient with CIVIL who took 2000 mg of imatinib as a single dose together with broti-zolam and triazolam in an attempt to commit suicide.
展开▼
